Last reviewed · How we verify
Combination of low ICS and montelukast
Combination of low ICS and montelukast is a Small molecule drug developed by Ajou University School of Medicine. It is currently FDA-approved.
At a glance
| Generic name | Combination of low ICS and montelukast |
|---|---|
| Sponsor | Ajou University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Asthma Research in Children and Adolescents
- Asthma Control in Elderly Patients With Montelukast (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of low ICS and montelukast CI brief — competitive landscape report
- Combination of low ICS and montelukast updates RSS · CI watch RSS
- Ajou University School of Medicine portfolio CI
Frequently asked questions about Combination of low ICS and montelukast
What is Combination of low ICS and montelukast?
Combination of low ICS and montelukast is a Small molecule drug developed by Ajou University School of Medicine.
Who makes Combination of low ICS and montelukast?
Combination of low ICS and montelukast is developed and marketed by Ajou University School of Medicine (see full Ajou University School of Medicine pipeline at /company/ajou-university-school-of-medicine).
What development phase is Combination of low ICS and montelukast in?
Combination of low ICS and montelukast is FDA-approved (marketed).